NASDAQHealth CareMedical DevicesSnapshot 2026-07-23
Reading VREX? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. VREX is currently loss-making but has shown strong recent financial performance, indicating potential for future growth.
The market appears to have priced in a low level of fragility, with valuation considered cheap compared to peers. There is an expectations gap, suggesting that investors may not fully anticipate the company's future revenue growth.
Management is focused on achieving revenue growth of $860M-$880M for FY 2026, with recent results aligning with this target. However, the company is currently not making a profit, and there is mixed progress towards its EPS goals.
The thesis relies on the performance of sector bellwethers like ABT, SYK, and MDT. If these companies continue to perform well, it could positively impact VREX. Conversely, any negative guidance from these peers could pose a risk to VREX's growth outlook.
Over the next 1 to 3 years, VREX's prospects depend on its ability to grow revenues while navigating the challenges of being a smaller-cap company. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings will provide insights into revenue and EPS progress. It is a key event for investors.
Confirms one read:Q3 earnings show strong revenue and EPS results, boosting investor confidence.
Confirms the other:Q3 earnings report shows weak results. This raises worries about growth and making money.
Why it matters: Meeting or exceeding guidance would show strong demand and support revenue growth goals for FY 2026.
Confirms:Q3 revenue reported at $225 million or higher.
Disproves:Q3 revenue reported below $210 million.
Why it matters: Good capital allocation helps the company grow and stay stable. It affects future investments.
Confirms one read:Management has a clear plan for spending money in Q3 earnings.
Confirms the other:No news or unclear plans on how money will be spent in Q3 earnings.
Why it matters: Health Care sector growth impacts Varex's performance. A rebound can boost revenue.
Confirms:Health Care sector reports revenue growth above 10% year over year.
Disproves:Sector growth is under 5%, showing ongoing challenges.
Why it matters: Meeting the EPS target is important. It shows that the company is making more money. This affects how investors feel.
Confirms:Q3 non-GAAP EPS reported at or above $0.40, showing progress towards the target.
Disproves:Q3 non-GAAP EPS is below $0.40. This shows that the company still has money problems.
Why it matters: The earnings report will show if Varex can improve its loss-making status. Investors will look for signs of recovery.
Confirms one read:Q2 earnings show smaller losses or a return to making money.
Confirms the other:Q2 earnings show losses that are worse than expected, indicating ongoing struggles.
Why it matters: An EPS of $0.15 or higher would indicate progress towards the annual target of $0.80-$1.00.
Confirms:Non-GAAP EPS reported at $0.15 or higher.
Disproves:Non-GAAP EPS reported below $0.15.
Why it matters: Stable cash flows show better financial health. This helps support growth plans.
Confirms:Cash outflows from operations are $0 or positive.
Disproves:Cash outflows from operations reported worse than -$2 million.
Why it matters: If sector revenue growth stays above average, it helps Varex grow in a good market.
Confirms one read:Sector revenue growth is above average.
Confirms the other:Sector revenue growth is below average.
